Loading...
NKTX logo

Nkarta, Inc.NasdaqGS:NKTX Aktierapport

Marknadsvärde US$230.4m
Aktiekurs
n/a
1Y84.0%
7D13.8%
1D13.0%
Portföljens värde
​
Utsikt

Nkarta, Inc.

NasdaqGS:NKTX Aktierapport

Börsvärde: US$230.4m

Nkarta (NKTX) Aktievy

Nkarta, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar och kommersialiserar naturliga mördarcellsterapier för behandling av cancer och autoimmuna sjukdomar. Mer information

NKTX fundamental analys
Snöflinga Score
Värdering2/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa6/6
Utdelningar0/6

Riskanalys

Ger mindre än 1 miljon USD i intäkter ( $0 )

Intäkterna förväntas minska med i genomsnitt 2.7% per år under de kommande 3 åren

För närvarande olönsamt och förväntas inte bli lönsamt under de kommande 3 åren

Volatil aktiekurs under de senaste 3 månaderna jämfört med US -marknaden


NKTX Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW495,270 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
495,270 investors already sharing narratives
View all narratives

Nkarta, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Nkarta
Historiska aktiekurser
Aktuell aktiekursUS$3.22
52 veckors högstaUS$3.65
52 veckors lägstaUS$1.68
Beta0.91
1 månads förändring28.29%
3 månaders förändring36.44%
1 års förändring84.00%
3 års förändring57.07%
5 års förändring-88.73%
Förändring sedan börsintroduktionen-93.28%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Nov 22

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Summary Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early preclinical results in B cell depletion and is advancing through Ntrust-1 and Ntrust-2 trials. NKTX boasts a strong cash position, providing over three years of operational runway, supporting continued research and development through key upcoming milestones. While clinical data is delayed to 1H 2026 and risks remain high, the current valuation undervalues NKTX’s potential, justifying a positive outlook. Read the full article on Seeking Alpha
Analysartikel • Nov 01

Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysartikel • Jul 15

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 31

Nkarta: Betting On The Turnaround

Summary Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention. Despite risks, NKTX is significantly undervalued with a potential upside; I plan to buy below $2.50 and target a sell at $7.05. Read the full article on Seeking Alpha
Analysartikel • Feb 27

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 02

Nkarta, Inc.: Trying To Find Space In A Crowded Place

Summary Nkarta has ceased development of NKX019 in lymphoma, focusing instead on autoimmune diseases. NKTX has $402.5M in cash and investments, which it estimates will last into late 2027. The name currently trades at less than half of cash. Cell therapy for autoimmune disease is a crowded space, but NKTX's ongoing trials, Ntrust-1 and Ntrust-2, in combination with two investigator sponsored trials, do give it multiple shots on goal. Read the full article on Seeking Alpha
Seeking Alpha • Oct 31

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Summary Nkarta is set to report data from its CAR-NK cell therapy, NKX019, used in a compressed dosing regime in lymphoma patients, in late 2024, possibly with Q3'24 earnings. NKTX seems increasingly focused on the development of NKX019 in autoimmune diseases, with trials of NKX019 in various autoimmune conditions underway already or soon to be underway. The Company faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning chemotherapy. Read the full article on Seeking Alpha
Analysartikel • Sep 10

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Nkarta ( NASDAQ:NKTX...
Seeking Alpha • Aug 14

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Summary Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell burden to go after and no tumor microenvironment. Data from the Ntrust-1 study targeting LN patients and results from Ntrust-2 targeting SSC, myositis and vasculitis, expected in 2025. Read the full article on Seeking Alpha
Seeking Alpha • May 23

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. The success of Nkarta's lead program, NKX019, in clinical trials will be crucial for the company's future and potential revenue generation. Read the full article on Seeking Alpha
Seeking Alpha • Apr 27

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Summary NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in oncology with more data coming mid-year. The work in autoimmune disease is just getting underway in H1'24. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Nkarta: NK Cell Therapy Advancement On Two Fronts

Summary Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036. NKX019 is also being used to target patients with autoimmune disorders like Lupus Nephritis; the first patient in the phase 1 study is to be dosed in 1st half of 2024. Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a public offering of $240 million was expected to close in March 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

Nkarta: Possible Upside From H1 Update, If Positive

Summary NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program. NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of 60% in patients with acute myeloid leukemia. The company's focus on a specific lymphodepletion regimen has shown better safety and durability outcomes, positioning them as a leader in the NK cell therapy space. Read the full article on Seeking Alpha
Analysartikel • Jan 16

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • Oct 04

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysartikel • Jun 21

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Mar 06

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Nov 20

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Nkarta GAAP EPS of -$0.61

Nkarta press release (NASDAQ:NKTX): Q2 GAAP EPS of -$0.61. Cash and Cash Equivalents: As of June 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $415.0 million.
Analysartikel • Jun 09

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 20

Nkarta: A Promising Natural Killer Cell Play

The market has favorably appreciated Nkarta’s recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the actual share price, possibly due to the market’s lack of insight in the highly innovative nature of the science. I give my take on Nkarta’s science, its recent readout, and its competitors. The stock is a long-term buy for me, but I do advise further investment diversificationin similar companies.
Analysartikel • Aug 23

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • May 10

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Jan 25

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Aktieägarnas avkastning

NKTXUS BiotechsUS Marknad
7D13.8%4.1%1.6%
1Y84.0%41.1%18.6%

Avkastning vs industri: NKTX översteg US Biotechs branschen som gav 41.1 % under det senaste året.

Avkastning vs Marknaden: NKTX översteg US marknaden som gav 18.6 % under det senaste året.

Prisvolatilitet

Is NKTX's price volatile compared to industry and market?
NKTX volatility
NKTX Average Weekly Movement13.6%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stabil aktiekurs: NKTX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: NKTX s veckovolatilitet ( 14% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
2015108Paul Hastingswww.nkartatx.com

Nkarta, Inc, ett biofarmaceutiskt företag i klinisk fas, utvecklar och kommersialiserar naturliga mördarcellsterapier för behandling av cancer och autoimmuna sjukdomar. Bolagets ledande produktkandidat är NKX019, en chimär antigenreceptor-naturlig mördare (CAR NK) inriktad på CD19-antigenet, som befinner sig i klinisk fas 1-studie för behandling av lupusnefrit, systemisk skleros, idiopatisk inflammatorisk myopati och ANCA-associerad vaskulit (antineutrofil cytoplasmatisk antikropp), samt för systemisk lupus erythematosus och myasthenia gravis. Bolaget har ett avtal om forskningssamarbete med CRISPR Therapeutics AG.

Nkarta, Inc. Sammanfattning av grunderna

Hur förhåller sig Nkarta:s resultat och omsättning till dess börsvärde?
NKTX grundläggande statistik
BörsvärdeUS$230.38m
Vinst(TTM)-US$99.93m
Intäkter(TTM)n/a
0.0x
P/S-förhållande
-2.3x
P/E-förhållande

Är NKTX övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
NKTX resultaträkning (TTM)
IntäkterUS$0
Kostnad för intäkterUS$0
BruttovinstUS$0
Övriga kostnaderUS$99.93m
Intäkter-US$99.93m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-1.40
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande0%

Hur har NKTX utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/05 12:37
Aktiekurs vid dagens slut2026/07/02 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Nkarta, Inc. bevakas av 9 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
William MaughanCanaccord Genuity
Joshua SchimmerEvercore ISI
Emily BodnarH.C. Wainwright & Co.